How does Nabota compete against Botox and Dysport?

Nabota competes primarily on price and local market knowledge in Asia, leveraging regional manufacturing and regulatory familiarity. As a locally-produced alternative, it undercuts Western brands while benefiting from established distribution networks and trust in South Korean and other Asian markets.

Will Asian botox brands enter the US market?

Asian manufacturers like Daewoong are likely to pursue U.S. entry through either FDA approval or acquisition by larger pharmaceutical companies as they consolidate market share in their home regions. This represents a long-term competitive threat to the current AbbVie-Galderma duopoly in the American aesthetics market.

What does the Asian toxin market milestone mean for US med spa pricing?

The maturation of regional injectable ecosystems signals long-term pricing pressure on U.S. practitioners as global supply chains diversify and new competitors emerge. Practice owners should expect competitive pricing dynamics to shift as non-Western manufacturers gain scale and potentially enter the U.S. market.

Is the Botox and Dysport duopoly in the US changing?

The rise of successful regional players like Nabota demonstrates that the AbbVie-Galderma duopoly is not inevitable. As Asian manufacturers prove viability and profitability in their home markets, they will increasingly target U.S. market entry, fragmenting the current two-player dominance.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

Daewoong's Nabota Hits 1 Trillion Won in Cumulative Sales—Asian Toxin Market Matures

Q: What is Nabota and how much has it sold?

Nabota is a botulinum toxin type A manufactured by South Korean company Daewoong Pharmaceutical. It has achieved over 1 trillion won (approximately $750 million USD) in cumulative lifetime sales, making it the leading botulinum toxin in South Korea with expanding presence across Asian markets.

South Korean botulinum toxin reaches milestone as Asian aesthetics market consolidates around regional players.

By Evan at Inside MedSpa · Jul 27, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Daewoong Pharmaceutical's Nabota (botulinum toxin type A) has surpassed 1 trillion won (approximately $750 million USD) in cumulative lifetime sales, underscoring the maturation and scale of the Asian aesthetics market. Nabota is the leading botulinum toxin in South Korea and has expanded into other Asian markets, competing against Botox and Dysport on price and local market knowledge.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/daewoong-nabota-1-trillion-won-sales/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Daewoong's Nabota Hits 1 Trillion Won in Cumulative Sales—Asian Toxin Market Matures

Share

Discussion

Leave a comment

By the time it's news, it's too late.